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Introduction
Tuberculosis is one of the 10 causes of death worldwide 
[1]. The lack of an appropriate and adequate treatment ac-
cording to the drug resistance profile contributes to the 
death in a couple of years [2]. The main objectives of the an-
ti-tuberculosis treatment constitute: 1. To cure the patient; 
2. To prevent the death from active disease or its late effects; 
3. To prevent relapse of tuberculosis; 4. To decrease the risk 
of the mycobacteria transmission to others; 5. To prevent 
the development of the acquired drug resistance [1, 2].
According to the World Health Organization guideline 
“Treatment of tuberculosis” and TB report drug susceptible 
tuberculosis is treated with the first-line anti-tuberculosis 
drugs: isoniazid, rifampicin, ethambutol, pirazinamide and 
streptomycin [1, 2]. Tuberculosis determined by the mul-
tidrug resistant strains (MDR-TB) is treated during 18-24 
months with 2nd line antituberculosis drugs according to 
the drug susceptibility test [3]. The standard treatment for 
MDR-TB consists in injectable antibiotics – aminoglyco-
zides (kanamycin, amikacin or capreomycin) and orally 
administrated anti-tuberculosis drugs: fluoroquinolones 
(levofloxacin, moxifloxacin or gatifloxacin), ethionamide, 
prothionamide, paraaminosalicylic acid and cycloserine) 
[1, 2]. There are 3 types of the anti-tuberculosis treatment 
administration options: 1. Community or home-based di-
rectly observed treatment (DOT) when the treatment is 
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Abstract 
Background: It is known that the main barriers in the anti-tuberculosis treatment delivery are social, economic, educational and psychological issues. 
According to the estimations the Republic of Moldova (RM) remains a high risk zone showing an inadequate concern regarding social determinants 
that represent the risk factors for achieving high treatment outcome. Tuberculosis is concentrated in areas with high density of the population, poor 
environmental and sanitation conditions: poverty, food insecurity, low living conditions.
Material and methods: A retrospective selective, descriptive study of socioeconomic, epidemiological peculiarities, case-management, diagnosis and 
microbiological characteristics of 693 patients with tuberculosis registered in Chisinau in 2016 was performed.
Results: Despite the fact that criteria for selection of patients for video-assisted anti-tuberculosis treatment (VOT) were defined, a range of risk factors 
can endanger treatment performing, such as: deep social economic vulnerability, comorbidities associated or not with psychic impairment, disease 
related characteristics, such as extensiveness, severity, duration of the tuberculosis evolution, positive microbiological state and multi-drug resistance 
are conditions which can exclude the ambulatory treatment and VOT. The low treatment outcome shows the limited potential of VOT to improve the 
epidemiological indices due to the complexity of patient’s risk factors.
Conclusions: VOT can be implemented in the management of tuberculosis patients in the actual epidemiological state of the RM, if a complex of patients 
supporting measures are performed.
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delivered in the community close to the patient’s home or 
work [1, 2]; 2. DOT administered by specialised healthcare 
providers such as in the hospitals or specialised services [1, 
2]; 3. Video-observed treatment (VOT), based on the prin-
ciple when the staff involed in its performing can observe 
the administration of the anti-tuberculosis drugs using elec-
tronic devices (personal computer, notebook, smartphone 
with Android system) through a web camera [3, 4, 5].
The technology required for VOT are broadband Inter-
net and availability of an electronic device connected to a 
specialised in VOT platform. The option for VOT is real-
time communication or recorded video. VOT can replace 
the DOT when video communication technology is avail-
able and the healthcare providers and the patients are well 
trained. VOT allows to observe adherence to treatment 
from distance, avoiding the direct contact of the patient with 
the healthcare worker. VOT is more flexible for patients, 
achieves a higher level of interaction between patients and 
medical staff and probably has a lower cost than DOT [6]. 
There were performed cohort studies in high income coun-
tries and no data were found from low and middle income 
countries which compared the treatment effectiveness of 
DOT compared with VOT [3, 4]. The studies showed that 
there is no statistical difference in the treatment completion 
and mortality among the groups treated through DOT and 
VOT [2, 3, 4].
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In the Republic of Moldova the methodology of the VOT 
was established by the law no. 153-XVI of 4.07.2008 related 
to the control and prevention of tuberculosis, recommen-
dations of the National Tuberculosis Control Program for 
2016-2020, approved by the decision no. 1160 of 20.10.2016, 
the objective of the Strategic Program for the Technological 
Upgrade of the Government (E-Transformare) approved by 
the decision no. 710 of 10.09.2011 and the National Clinical 
Protocol “Tuberculosis in adults” 123 approved by the deci-
sion no.1081 of 29.12.2017. The regulation established that 
the responsibility for the initiation of the VOT lies on the 
pulmonologist specialised in tuberculosis and the primary 
healthcare worker responsible for the case management in 
the outpatient settings. In the Republic of Moldova the VOT 
facilitates the interaction between the healthcare worker 
and the patient; however, it does not replace the DOT. The 
including criteria for video-observed treatment (VOT) in 
the RM are: 1) The patient has an available electronic device 
(personal computer, notebook, smartphone with android 
system) and a web camera through which the medical staff 
involed in its performing can observe the administration 
of the anti-tuberculosis drugs; 2) The patient is residing in 
the RM. 3) the patient can administrate independently the 
anti-tuberculosis treatment [7, 8, 9, 10, 11, 12]. The tech-
nologies required for VOT to be available for the patient are: 
broadband Internet and availability of an electronic device 
connected to a specialised in VOT platform. The option 
for VOT according to the actual regulation is the recorded 
video available to be sent for validation through the VOT 
platform.
The steps to be performed by the trained in VOT health-
care worker are:
1. Before the initiation of the anti-tuberculosis treatment 
the patient must be informed by the healthcare worker about 
the possibility to accomplish it using the video-assistance.
2. To create an account on the site www.vot.tuberculosis.
md on E-Sanatate platform on the page ”Medici”.
3. Before the initiation the VOT the healthcare worker 
should identify if the patient is eligible according to the in-
cluding criteria established in the ”Eligibility Checklist for 
Including in VOT”.
4. If the patient accomplishes 14 days of 100% treatment 
compliance the healthcare worker will appreciate him eli-
gible according to the evaluation form ”Eligibility Checklist 
for Including in VOT”.
5. After the patient’s assessment through the ”Eligibility 
Checklist for Including in VOT” the pulmonologist will de-
cide to include or exclude the patient from VOT.
6. The VOT will be monitored and followed-up accor-
ding to the recommendations of the National Clinical Pro-
tocol No 123 ”Tuberculosis in adults” [7, 11].
The trained patient will receive the anti-tuberculosis 
drugs for 14-30 days confirmed by the signature in the TB01 
register. Before the video recording the patient must pre-
pare the drugs on a white paper visible in the webcam and 
a transparent glass with water in an illuminated place. Af-
ter the onset of the video recording the patient has to pres-
ent himself and to enumerate the drugs prepared and the 
number of the pills. The patient should be placed in front of 
the webcam and to swallow the drugs one by one with the 
water prepared in the transparent glass. The patient has to 
open the mouth and to show the tongue after the swallow-
ing of the pills. At the end of the administration the patient 
will stop the video recording and will send to validation. 
The healthcare worker must assess and validate the video 
recording from 1 to 3 points. The value 1 means the treat-
ment was administrated and the dose was validated. The 
value 2 means that there is no certainty that the pills were 
swallowed. The value 3 means that the treatment was not 
administrated or the dose of a drug was not swallowed. The 
patient is responsible for the storing the anti-tuberculosis 
drugs in special conditions such as dry and dark place, far 
from children. 
The regulation establishes excluding from VOT criteria 
or criteria which cannot allow the patient to be enrolled in 
VOT. The patient should be treated using the DOT instead 
of VOT if: a) he refuses to sign the informed consent for 
VOT; b) the therapeutic regimen includes injectable drugs; 
c) the patient has no available electronic device (personal 
computer, notebook, smartphone); d) the electronic de-
vice has no Internet connection or the connection has a 
low speed; d) the patient is unable to take independently 
the anti-tuberculosis drugs, e) the patient is diagnosed with 
mental disorders.
There are several criteria which ensure the transfer of 
the patient from VOT to DOT: a) the patient’s requirement; 
b) the patient fails to transmit for validation the recorded 
video for at least 2 days; c) the patient does not answer the 
telephone; d) the hospitalisation in the emergency depart-
ment; e) imprisonment; f) the patient left the Republic of 
Moldova for more than 1 month; g) the patient has a low 
tolerance of the anti-tuberculosis drugs or experiences ad-
verse drug effects; h) the referral pulmonologist decides to 
stop the VOT.
Before the initiation of the VOT the healthcare worker 
must register the patient on the site www.vot.tuberculoza.
md and complete the electronic file of the health state (”Do-
sarul electronic de sănătate) with the patient’s data about 
diagnosis and treatment. Special duties are attributed to the 
nurse specialized in the case management, such as: 
1. Supporting the patient in the creating the account on 
www.vot.tuberculoza.md, 
2. To explain what means VOT and its principles; 
3. To establish the number of the doses, the frequency of 
the administration, the modality of the video recording and 
sending for validation, the steps to be followed in different 
issues (technical problems, lack of electricity, low Internet 
speed).
4. To receive and to validate the video files and to con-
firm the administration of the anti-tuberculosis drugs ac-
cording to the recommended regimens.
5. To complete the treatment register TB01 after the 
VOT video files validation.
6. To explain and ensure that the patient could recognize 
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the clinical signs of the adverse drug reactions and declare 
them.
However, the main barriers in the anti-tuberculosis 
treatment delivery are social, economic, educational and 
psychological issues [7, 9, 13, 14, 15]. According to the es-
timations the Republic of Moldova (RM) remains a high 
risk zone showing an inadequate concern regarding social 
determinants, that represent the risk factors for achieving 
high treatment outcome. Tuberculosis is concentrated in ar-
eas with high density of the population, poor environmental 
and sanitation conditions: poverty, food insecurity, low liv-
ing conditions. The most affected groups, being assessed as 
hard-to-reach groups, are homeless, migrants, individuals 
living with HIV, drug injected users, alcohol abusers. Ac-
cumulated evidence suggested that not only the deficiencies 
in performing an effective antituberculosis treatment is a 
problem for the public health care system, but also the lack 
of intervention to resolve social and economic problems of 
tuberculosis patients. All factors that diminish the treatment 
success rate could be assessed as excluding criteria from the 
VOT. In this paper we evaluated tuberculosis patients di-
agnosed in Chisinau according to the social, demographic 
and economic characteristics for identifying target groups 
for VOT. So, the aim of the study was to assess the including 
and excluding criteria from VOT in a cohort group of tuber-
culosis patients from Chisinau city. The objectives were: 1. 
Assessment of the socioeconomic and epidemiological risk 
factors of patients with tuberculosis distributed in includ-
ing and excluding for VOT criteria. 2. Evaluation of the case 
management, diagnosis, radiological patterns and microbi-
ological characteristics of tuberculosis patients distributed 
in including and excluding for VOT criteria. 
Material and methods
It was performed a retrospective selective, descriptive 
study targeting social, demographic, economic and epide-
miological peculiarities, case-management, diagnosis, ra-
diological aspects and microbiological characteristics of 693 
patients registered with tuberculosis in Chisinau in 2016. 
The electronic system for monitoring and follow-up of tu-
berculosis cases (SIME TB) was used for the selection. Data 
were extracted from the statistic templates F089/1-e “Decla-
ration about the patient’s established diagnosis of new case/
relapse of active tuberculosis and restart of the treatment 
and its outcomes” and F090/e “Declaration and follow up 
of multidrug-resistant tuberculosis”. The inclusion criteria 
were: age more than 18 years old, tuberculosis diagnosed 
by the specialist and signed informed consent. All patients 
with tuberculosis were investigated and treated according to 
the National Clinical Protocol 123 “Tuberculosis in Adults” 
[8]. Statistic analysis was carried out using the quantitative 
and qualitative research methods [16]. 
Results and discussion
According to the data obtained from the monitoring and 
follow-up of the cases during the period of 2016, were regis-
tered 693 tuberculosis cases among all residents of Chisinau, 
which included 581 (84%) patients from the urban sectors 
and 112 (16%) from rural communes. So, the VOT could be 
implemented mainly in patients from urban sectors where 
broadband Internet and electronic devices connected to 
specialize in VOT platform are more available than in ru-
ral regions. While distributing selected patients according 
to the sex, it was established the statistical predominance of 
men 474 (68%) compared with women 219 (31%), with a 
male/female rate 2.1/1 (fig 1). 
Repartition of patients into age groups, according to 
the WHO recommendation identified that the largest sub-
groups were between 25 and 34 years old, and also between 
35 and 44 years old, respectively 173 (25%) and 162 (23%) 
patients. Less numerous were patients from the subgroups 
45-54 years old – 116 (17%), 55-64 years old – 100 (14%), 
18-24 years old – 78 (11%) and older than 65 years – 64 
(9%) patients. The total number of young patients who were 
between 18 and 44 years old constituted 413 (60%), which 
showed that VOT should target young patients (fig. 2).
Fig. 1.  Distribution of patients by sex and demographic 
residence (%).
Fig. 2.  Distribution of patients by age (%).
When distributing patients, according to the economic 
status, it was established that the were 158 (23%) employed 
persons, contributing to the health budget by paying taxes. 
So, according to the economic segregation of the patients, 
the financial capacity for supporting the VOT by acquiring 
electronic devices, such as personal computer, notebook, 
smartphone connected to a broadband Internet could have 
only one fourth. 82 (12%) patients were retired. Older than 
65 years were 83 (12%) patients, being eligible for VOT, 
however, they are less likely to use electronic devices con-
nected to a broadband Internet.  61 (9%) patients were 
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disabled, which have a high risk to be excluded due to the 
incapacity to take the pills independently. Unemployed pa-
tients made up the majority of the group – 377 (54%) cases, 
which can also be excluded due to the economical incapac-
ity. There were 14 (2%) pupils and students. Most of them 
should be excluded due to the age criteria and the fact that 
they form infectious clusters made up preponderantly by 
children (fig. 3).
Fig. 3.  Distribution of patients in economic subgoups (%).
Assessing the educational level, we established that 
most of the patients had secondary education – 291 (42%) 
cases. Technical vocational education had 181 (26%) and 
bachelor studies – 49 (7%) patients. So, according to the 
educational level, 521 (75%) could be eligible to perform 
VOT, considering their intellectual ability to use electronic 
devices (personal computer, notebook, smartphone). 
Lack of studies, only primary and incomplete secondary 
education were established in each fourth patient – 172 
(25%) and could not be eligible for VOT (fig. 4).
Fig. 4.  Distribution according to the last graduate level (%).
The extreme poverty, caused by homelessness or lack of 
the demographic registration was identified in each fourth 
patient – 147 (21%). So, certainly every fourth patient will 
not be eligible for VOT. Migrants were defined persons who 
left the Republic of Moldova for more than 3 months during 
the year of the tuberculosis diagnosis. One of excluding 
criteria for VOT is the situation when the sick person leaves 
the Republic of Moldova for more than 1 month. The data 
confirmed that 70 (10%) patients are not eligible for VOT 
because they could be lost from follow-up due to their 
absence in the Republic of Moldova. The history of detention 
during the last year was identified in 38 (5%) cases. This type 
of patients is not eligible for VOT according to the regulation 
establishing the conditions for VOT (fig. 5).
Fig. 5.  Excluded from VOT patients.
Close infectious contact with a member of a family who 
was previously diagnosed with tuberculosis was established 
in 70 (11%) patients. The ambulatory treatment of the 
patients from infectious clusters makes the video-assistance 
a challenge. The VOT of patients with associated diseases 
raises big issues due to frequent severe adverse drug effects, 
incapacity to recognize them and to perform independently 
the treatment. Hospitalization in other departments than 
those specialized in the treatment of tuberculosis is a 
criteria which stops VOT and starts the DOT. There were 
225 (32%) comorbid patients, which shows that each third 
case has a high risk to be transferred from VOT to DOT 
or to be illegible for video-assistance. Among comorbidities 
predominated HIV-infection – 62 (9%). The co-infection 
TB-HIV raises the rate of severe and disseminated forms 
with high risk of death. Those conditions make impossible 
the treatment in ambulatory conditions and make the 
patients not eligible for VOT. In a high proportion were 
diagnosed patients with chronic alcoholism – 59 (8.5%). 
Drug users were 10 (1.4%) patients. Psychiatric diseases were 
diagnosed in 12 (5%) patients. Numerous mental disorders 
were diagnosed in 81 (12%) and constitute certain exclusion 
criteria from the VOT. Diabetes mellitus was diagnosed in 
11 (5%) cases. Due to a high rate of adverse drug effects 
diabetic patients have a high risk to be excluded from VOT. 
Immune suppressive conditions such as neoplastic diseases, 
treatment with corticosteroids and chronic renal failure 
were diagnosed in 15 (2%) cases (fig. 6). Due to frequent 
hospitalizations of immune suppressed patients they will be 
excluded from VOT.
 
 
Fig. 6.  Distribution according to the risk groups.
Note:  IST-immune suppressive treatment.
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Studying case-management, it was identified that the 
general practitioners were involved in the detection of 
the most of the patients – 299 (43%) and the specialists 
detected 210 (30%) patients. Screening of the patients from 
high risk groups performed by the general practitioners 
detected 82 (12%) cases and through the investigation 
of the symptomatic cases were detected 217 (31%) cases. 
Pulmonologists detected 167 (24%) symptomatic patients 
and 43 (6%) from high risk groups. 43 patients (6%) came 
directly for hospitalization into a specialized institution and 
were hospitalized due to the personal requirement. Most 
of those patients were not admitted for the ambulatory 
treatment and could not be eligible for VOT.
While distributing patients, according to the registered 
case type, it was identified that the new cases, never 
treated cases, predominated – 425 (61%) compared with 
the relapses – 165 (24%) cases. New cases and relapses are 
eligible for VOT and their number constituted 590 (85%) 
with other excluding criteria will not be identified. Patients 
recovered after a previous “loss to follow-up" made up 69 
(10%) and treatment failure – 31 (5%). The total number of 
the patients previously treated and not allowed for VOT due 
to the therapeutic incompliance was 100 (15%) cases (fig. 8).
Fig. 7.  Distribution according to the medical staff involved in 
the case detection.
Fig. 8.  Distribution according to the case type.
While identifying the clinical, radiological forms of tu-
berculosis, it was established that pulmonary forms were 
diagnosed in a higher proportion 656 (94%) cases. Ex-
trapulmonary forms of tuberculosis were diagnosed in 34 
(5.4%) patients. Generalised tuberculosis was diagnosed 
in 3 (0.4%) cases. Severe with extensive destructions pul-
monary infiltrative tuberculosis – caseous pneumonia was 
diagnosed in 41 (6%) cases. Disseminated tuberculosis and 
fibro-cavernous tuberculosis were diagnosed in 60 (8%) pa-
tients. Severe, disseminated, generalised and chronic forms 
of tuberculosis can not be treated in ambulatory conditions 
due to the risk of death and were diagnosed in at least 104 
(15%) patients. Extended tuberculosis in both lungs was di-
agnosed in two thirds of patients – 484 (70%), which can 
raise difficulties for ambulatory treatment.
Fig. 9.  Distribution according to the clinical radiological forms.
Note: PIT – pulmonary infiltrative tuberculosis, FCVT – fibro-cavernous 
tuberculosis, PDT – pulmonary disseminated tuberculosis.
When assessing the laboratory features of the enrolled 
pulmonary tuberculosis patients, it was identified that 
one third of the entire sample was microscopic positive 
for acid-fast-bacilli, 200 (29%) patients. Microscopic posi-
tive patients are non-eligible for ambulatory treatment due 
to epidemiological threat, which they expose on the fam-
ily and social community. A lower proportion of patients 
were identified to have positive bacteriological results at 
cultivation on solid Lowenstein-Jensen ether liquid MGIT 
BACTEC media: 144 (21%) patients. The molecular genetic 
assay was performed in all cases, but positive results were 
obtained in 278 (40%) cases, including rifampicine sensitive 
were 179 (26%) and resistant 99 (14%) cases. Microscopi-
cally positive for AFB and cultivation on the conventional 
media established Mycobacterium tuberculosis (MTB) in 
104 (15%) being assessed as non-eligible for the ambulatory 
treatment. Patients with MDR-TB should be treated com-
pulsory during the intensive phase, for 6 months, in the hos-
pital due to the therapeutic regimen, which includes inject-
able drugs. So, 116 (17%) of patients were not allowed for 
VOT for the treatment in ambulatory conditions and VOT 
during the intensive phase (fig. 10).
The standard treatment for the new drug-susceptible 
tuberculosis in the RM has been used since 2000, lasts 6 
months and consists of two phases with four first-line drugs: 
isoniazid (H), rifampicin (R), ethambutol (E) and pyrazina-
mide (Z) in the intensive phase and two first-line drugs: iso-
niazid and rifampicin in the continuation phase. For previ-
ously treated cases was used a regimen which lasts 8 months: 
2 months with H, R, E, Z, S and 1 month with H, R, E, Z and 
5 months with H, R and E. Patients with rifampicin-resist-
ant or MDR-TB were treated with second-line drugs for 18 
months or more divided in two phases The regimen com-
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position during the intensive phase lasts 6 months and in-
cluded kanamycin (Km) or capreomycin (Cm), levofloxacin 
(Lfx), para-amino salicylic acid (PAS), ethionamide (Eto), 
cycloserine (Cs) and pyrazinamide (Z) and for continua-
tion phases during 12-18 months of Lfx, PAS, Etho, Cs and 
Z. The standard treatment for drug susceptible tuberculo-
sis with first-line anti-tuberculosis drugs was used for the 
treatment of 577 (83%) cases and for MDR-TB with second-
line anti-TB drugs were treated 116 (17%), of which 7 (1%) 
patients with extensive drug resistance (XDR-TB) should be 
treated in specialized service.
All the patients were managed and treated with the 
standard treatment for tuberculosis. First-line anti-tuber-
culosis drugs were used in 577 (83%) patients from urban 
groups vs. 13 (11.7%) patients from the rural group. Suc-
cessfully treated were 450 (65%) cases, failed the treatment 
– 9 (1%), were lost to follow-up –51 (7%) cases and died 81 
(12%) patients. 61 (9%) patients were still continuing the 
treatment and not available data was established in 41 (6%) 
cases, which are the candidates for lost to follow – up. So, 
the low therapeutic outcome, which included therapeutic 
failure, lost to follow-up and patients without available out-
come was established in every third case – 182 (26%). Infor-
mation is exposed in the figure 11. 
Fig. 11.  Treatment outcome of tuberculosis patients.
An important research outcome represents the groups of 
patients in which the priority interventions for implemen-
tation of VOT are most suitable and the groups of patients 
which the excluding criteria will not allow to start the VOT. 
It was established that the risk factors which contribute to 
the excluding from VOT or the transfer from VOT to DOT 
were linked with the sociovulnerability: unemployment, 
low level of the school education, homelessness or lack of 
the residence visa, harmful habits, migration, present em-
prisonment or history of imprisonment. Medical biologi-
cal conditions which contribute to the excluding or lack of 
eligibility for VOT are: comorbidities, mental disorders and 
harmful habits with mental impairment. Epidemiological 
risk factors which arise challenges for the ambulatory treat-
ment were close contact and clusters composed by children. 
Disease related characteristics which make non-eligible pa-
tients for ambulatory treatment are severe, extended, dis-
seminated and chronic evoluated tuberculosis. Every tenth 
patient could not be allowed for VOT due to the enumer-
ated conditions. One third of the groups were microscopic 
positive for AFB, which exclude the possibility for the am-
bulatory treatment and VOT as well. Second-line anti-tu-
berculosis treatment with injectable drugs in the intensive 
phase was used for the treatment of 17% of patients which 
make them non-eligible for the video-assistance. Generally, 
the treatment outcome did not achieve the 85% of success, 
as recommended by WHO [1]. The final results were di-
minihsed by a high proportion of patients, which had a low 
outcome due to therapeutic incompliance, severe forms of 
tuberculosis and comorbidities.
The relation between tuberculosis indices and treatment 
delivery was widely studied [1, 2]. Globally, the epidemic 
of tuberculosis is much higher in socially vulnerable sub-
populations [1, 2]. It can be explained by the complexity 
of risk factors, which reflects the barriers for accessing the 
healthcare services and to achieve the treatment comple-
tion [3, 4, 5]. In the RM the specialised institutions offer a 
standard approach, which corresponds to the international 
recommendation and national regulations [10, 11]. The ac-
tual international recommendation imposes the ambula-
tory treatment of tuberculosis patients and implementation 
of VOT instead of DOT. Our research established increased 
rate of socially vulnerable patients (unemployed, homeless, 
migrants, patients with history of imprisonment) with low 
degree of school education which can reduce the effective-
ness of the VOT implementation. No similar studies assess-
ing the impact of social vulnerability on VOT were iden-
tified. Tuberculosis indices are linked with overcrowding, 
low level of sanitation and infectious clustering, which also 
endanger the treatment results; however, no studies assessed 
these conditions. Disease related characteristics, such as ex-
tensiveness, severity, duration of the tuberculosis evolution, 
drug resistance spectrum were not included as conditions 
with high impact on the treatment outcome in the interna-
tional papers. 
Conclusions
VOT represents a modality for the anti-tuberculosis 
treatment delivery in high income countries.  VOT facili-
tates the interaction between the healthcare worker and the 
Fig. 10.  Distribution according to the microbiological 
characteristics.
Note: MBT – Mycobacteria tuberculosis, AFB – acid fast bacilli, Rif – 
rifampicine.
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patient, however, it does not replace the DOT in tuberculo-
sis treatment.
The including criteria for video-observed treatment 
(VOT) in the RM are: 1) the patient has an available elec-
tronic device 2) the patient is residing in the RM. 3) the pa-
tient can administrate independently the anti-tuberculosis 
treatment. 
The informal excluding criteria from VOT were deep 
social economic vulnerability, associated or not with migra-
tion, homelessness, detention and infectious clustering.
Associated diseases, which can reduce the VOT effec-
tiveness are those which reduce the immune resistance (TB-
HIV, diabetes mellitus, immune suppressive treatment, neo-
plastic diseases) and which exclude patients due to psychic 
impairment (psychiatric disorders, harmful habits such as 
chronic alcoholism and drug use).
Disease related characteristics, such as extensiveness, 
severity, duration of the tuberculosis evolution, positive mi-
crobiological state and multi-drug resistance are conditions 
which can exclude the ambulatory treatment and VOT as 
well.
The low treatment outcome during DOT shows indi-
rectly that VOT will not improve the outcome due to the 
complexity of patient’s risk factors.
VOT can be implemented in the management of tuber-
culosis patients in actual epidemiological state of the RM, 
if a complex of patients supporting measures is performed.
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